Search research articles
Contact Us
Filters
Showing results (61-70 of 73) with videos related to
Page
of 8
Sort By:
Brain : a Journal of Neurology
|
September 30, 2019
Human CCR5high effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis
Sebastian Herich, Tilman Schneider-Hohendorf, Astrid Rohlmann, et al.
Journal of Autoimmunity
|
March 5, 2025
Differences in innate immune cell populations distinguish autoimmune from herpesvirus-associated encephalitis
Saskia Räuber, Andreas Schulte-Mecklenbeck, Kelvin Sarink, et al.
Cell Reports. Medicine
|
June 25, 2024
Chemokine-mediated cell migration into the central nervous system in progressive multifocal leukoencephalopathy
Marie Deffner, Tilman Schneider-Hohendorf, Andreas Schulte-Mecklenbeck, et al.
Nature Medicine
|
September 22, 2023
A H3K27M-targeted vaccine in adults with diffuse midline glioma
Niklas Grassl, Isabel Poschke, Katharina Lindner, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 21, 2010
Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes
Michele P Kelly, Sheree F Logue, Julie Brennan, et al.
Cancer Immunology Research
|
October 11, 2019
Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF
Mariangela Di Tacchio, Jadranka Macas, Jakob Weissenberger, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
January 10, 2008
Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide (WAY-101405)
Warren D Hirst, Terrance H Andree, Suzan Aschmies, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 16, 2009
WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity
Julie A Brennan, Radka Graf, Steven M Grauer, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 2, 2009
Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia
David P Rotella, Geraldine R McFarlane, Alexander Greenfield, et al.
Nature Communications
|
April 8, 2026
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial
Frank A Giordano, Julian P Layer, Roberta Turiello, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 73) with videos related to
Sort By:
Page
of 8
Brain : a Journal of Neurology
|
September 30, 2019
Human CCR5high effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis
Sebastian Herich, Tilman Schneider-Hohendorf, Astrid Rohlmann, et al.
Journal of Autoimmunity
|
March 5, 2025
Differences in innate immune cell populations distinguish autoimmune from herpesvirus-associated encephalitis
Saskia Räuber, Andreas Schulte-Mecklenbeck, Kelvin Sarink, et al.
Cell Reports. Medicine
|
June 25, 2024
Chemokine-mediated cell migration into the central nervous system in progressive multifocal leukoencephalopathy
Marie Deffner, Tilman Schneider-Hohendorf, Andreas Schulte-Mecklenbeck, et al.
Nature Medicine
|
September 22, 2023
A H3K27M-targeted vaccine in adults with diffuse midline glioma
Niklas Grassl, Isabel Poschke, Katharina Lindner, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 21, 2010
Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes
Michele P Kelly, Sheree F Logue, Julie Brennan, et al.
Cancer Immunology Research
|
October 11, 2019
Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF
Mariangela Di Tacchio, Jadranka Macas, Jakob Weissenberger, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
January 10, 2008
Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide (WAY-101405)
Warren D Hirst, Terrance H Andree, Suzan Aschmies, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 16, 2009
WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity
Julie A Brennan, Radka Graf, Steven M Grauer, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 2, 2009
Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia
David P Rotella, Geraldine R McFarlane, Alexander Greenfield, et al.
Nature Communications
|
April 8, 2026
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial
Frank A Giordano, Julian P Layer, Roberta Turiello, et al.
Page
of 8